SAR103168: A tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

Leukemia and Lymphoma

Volumn 54, Issue 7, 2013, Pages 1488-1499

  Bourrié, Bernard ^a   Brassard, Diana L ^b   Cosnier Pucheu, Sylvie ^a   Zilberstein, Asher ^a   Yu, Kin ^b   Levit, Mikhail ^b   Gil Morrison, J ^c   Perreaut, Pierre ^a   Jegham, Samir ^a   Hilairet, Sandrine ^a   Bouaboula, Monsif ^b   Penarier, Geraldine ^a   Guiot, Cécile ^a   Larroze Chicot, Philippe ^a   Laurent, Guy ^d,e   Demur, Cécile ^d   Casellas, Pierre ^a  

^a SANOFI   (France)

^b Research and Development Center   (United States)

^c Sanofi Aventis Isotope Chemistry and Metabolite Synthesis Northumberland   (United Kingdom)

^d CHU PURPAN   (France)

^e Department of Pediatric Surgery   (France)

Author keywords

Myeloid leukemias; SAR103168; Tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CD135 ANTIGEN; CYTARABINE; DASATINIB; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; I KAPPA B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SAR 103168; STAT5 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TIPIFARNIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; CHROMOSOME 7; CHROMOSOME REARRANGEMENT; CHRONIC MYELOID LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; IC 50; IN VIVO STUDY; INDUCTION CHEMOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCID MOUSE; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKEMIA, MYELOID; MICE; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879370959     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.745071     Document Type: Article

References (33)

1. Estey E, D ?hner H. Acute myeloid leukemia. N Engl J Med 2006;368:1894-1907.
2. Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site, 2011. Available from: http://seer.cancer.gov/csr/1975-2008/
3. Schlenk RF, D ?hner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909-1918. (Pubitemid 351620111)
4. O zawa Y, W illiams A H, E stes M L, et al. S rc family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT). Leuk Res 2008;32:893-903.
5. Okamoto M, Hayakawa F, Miyata Y, et al. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 2007;21:403-410.
6. Dos Santos C, Demur C, Bardet V, et al. A critical role for Lyn in acute myeloid leukemia. Blood 2008;11:2269-2279. (Pubitemid 351451434)
7. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000;19:624-631. (Pubitemid 30102913)
8. M izuki M, F enski R, H alfter H, et al. F lt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 2000;96:3907-3914.
9. S chepers H, V an Gosliga D, W ierenga A T, et al. S TAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 2007;110:2880-2888. (Pubitemid 350006941)
10. F athi A T, G rant S, K arp J E. E xploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev 2010;36:142-150.
11. Grant S. New agents for AML and MDS. Best Pract Res Clin Haematol 2009;22:501-507.
12. Stone RM. Novel therapeutic agents in acute myeloid leukemia. Exp Hematol 2007;35:163-166. (Pubitemid 46427994)
13. Bao T, Smith BD, Karp JE. New agents in the treatment of acute myeloid leukemia: a snapshot of signal transduction modulation. Clin Adv Hematol Oncol 2005;3:287-296.
14. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999;94:3717-3721.
15. Wakabayashi M, Miwa H, Shikami M, et al. Autocrine pathway of angiopoietins-Tie2 system in AML cells: association with phosphatidylinositol 3 kinase. Hematol J. 2004;5:353-360. (Pubitemid 39214214)
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997;3:730-737. (Pubitemid 27298715)
17. Dick JE. Stem cell concepts renew cancer research. Blood 2008 ; 112:4793-4807.
18. Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells-targeting the evil twin. Nat Clin Pract Oncol 2008;5:337-347. (Pubitemid 351780950)
19. R ?cher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527-2534. (Pubitemid 40387055)
20. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumours xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802-820. (Pubitemid 38519759)
21. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of human genome. Science 2002;198:1912-1934. (Pubitemid 35425239)
22. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifranib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008;14:3077-3082.
23. Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel abl kinase inhibitor. Science 2004; 305: 399-401. (Pubitemid 38938156)
24. Miranda MB, Johnson DE. Signal transduction pathways that contribute to myeloid diff erentiation. Leukemia 2007;21:1363-1377. (Pubitemid 46965277)
25. M itina O, W armuth M, K rause G, et al. S rc family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann Hematol 2007;86:777-785. (Pubitemid 47497095)
26. Sampson M, Zhu QS, Corey SJ. Src kinases in G-CSF receptor signalling. Front Biosci 2007; 12: 1463-1474. (Pubitemid 46846845)
27. R obinson L J, X ue J, C orey S J. S rc family kinases are activated by Flt3 and are involved in the proliferative eff ects of leukemia-associated Flt3 mutations. Exp Hematol 2005;33:469-479.
28. Rao AV, Valk PJM, Metzeler KH, et al. Age-specific diff erences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol 2009;27:5580-5586.
29. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann NY Acad Sci 2006; 1086: 213-222. (Pubitemid 47084370)
30. C houdhary C, B randts C, S chwable J, et al. A ctivation mechanisms of STAT5 by oncogenic Flt3-ITD. Blood 2007;110:370-374. (Pubitemid 47026856)
31. L ombardo L J, L ee F Y, C hen P, et al. D iscovery of N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl) -2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661. (Pubitemid 40053752)
32. J ohnson F M, S aigal B, T alpaz M, et al. D asatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non small cell, lung cancer cells. Clin Cancer Res 2005; 11: 6924-6932. (Pubitemid 41428750)
33. N am S, K im D, C heng J Q, et al. A ction of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005; 65: 9185-9189. (Pubitemid 41507982)